{
    "clinical_study": {
        "@rank": "144797", 
        "arm_group": {
            "arm_group_label": "MT-1303", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate PK, PD and safety of a single oral dose of MT-1303\n      in subjects with Crohn's disease."
        }, 
        "brief_title": "Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "detailed_description": {
            "textblock": "This is a Phase I, open-label, non-randomised, multicenter single-dose study to evaluate PK,\n      PD, and safety of a single oral dose of MT-1303 in subjects with moderate to severe active\n      Crohn's disease (ileal and ileo-colonic type)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who were diagnosed as Crohn's disease\n\n          -  Subjects who were confirmed as ileal or ileo-colonic type by image inspection.\n\n          -  Disease severity determined as either \"moderate\" or \"severe\"\n\n        Exclusion Criteria:\n\n          -  Present or past history of gastrointestinal surgery which may have impact on drug\n             absorption\n\n          -  Subjects with stenosis or fistula in small intestine or colon"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "3", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02148185", 
            "org_study_id": "MT-1303-J02"
        }, 
        "intervention": {
            "arm_group_label": "MT-1303", 
            "intervention_name": "MT-1303", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Crohn's disease", 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }, 
                    "name": "Inverstigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }, 
                    "name": "Inverstigational site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Open-label Study to Evaluate PK, PD, and Safety of a Single Oral Dose of MT-1303 in Subjects With Moderate to Severe Crohn's Disease", 
        "overall_contact": {
            "email": "cti-inq-ml@ml.mt-pharma.co.jp", 
            "last_name": "Clinical Trials Information Desk"
        }, 
        "overall_official": [
            {
                "affiliation": "Tokyo Medical and Dental University", 
                "last_name": "Mamoru Watanabe, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Mitsubishi Tanabe Pharma Corporation", 
                "last_name": "Kazuoki Kondo, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Plasma concentration of MT-1303", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to 29 days"
            }, 
            {
                "measure": "Plasma concentration of MT-1303 metabolite", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to 29 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02148185"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in lymphocyte count after MT-1303 administration", 
                "safety_issue": "No", 
                "time_frame": "16 time points up to 29 days"
            }, 
            {
                "measure": "Type of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "29 days"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}